Earnings ·
Evolent Health reports Q3 revenue of $725.4M and raises full-year Adjusted EBITDA guidance to $130M-$135M
EVHEvolent Health, Inc.
Evolent Health reported third-quarter 2026 revenue of $725.4 million, up from $479.5 million in the prior year period, alongside a net loss attributable to common shareholders of $23.6 million compared to a $26.9 million loss previously. Adjusted EBITDA came in at $34.3 million against $39.0 million last year. The company reiterated its full-year 2026 revenue guidance range of $2.6 billion to $2.7 billion and raised its Adjusted EBITDA outlook to $130.0 million-$135.0 million, citing strong demand for complex specialty care solutions and successful oncology launches. Evolent Health specializes in improving health outcomes for people with complex conditions through technology and services that make healthcare simpler and more affordable.